2024 AAMRI Report

Every two years, AAMRI undertakes a survey of its members to develop the only benchmarking report produced for the Australian medical research sector.

The findings are incorporated into the 2024 AAMRI Report, which provides a comprehensive analysis of our sector’s workforce, competitive grant successes, financial performance, and research commercialisation and translation activities.

Two versions of the report are produced – a 102 page full analysis for AAMRI’s member institutes only, and a 40 page summarised public snapshot version, which is available below.

Key findings from the 2024 AAMRI Report:

• In 2023, our sector received almost $2.5 billion in total revenue and our researchers outperformed the average funded rate for major competitive grants.
• Our institutes brought innovative treatments to the Australian community through 2,046 clinical trials and established 23 spin-out companies to translate their research into new products and technologies. This included the first mechanically and acoustically-optimised prosthetic eardrum, rapid antimicrobial tests to identify effective antibiotics for patients, 3D-printed heart valve technology, and new evidence-based mental health treatments.
• Despite this, our institutes are under immense pressure to secure grant funding that supports the full costs of undertaking their lifesaving research and, overall, had to find an additional $786.2 million to cover the financial gap. To better understand the financial complexities faced by our sector, AAMRI’s Full Costs Committee has defined a new set of deeper performance metrics, which are being tracked for the first time in this year’s report.
• Positive progress in addressing workforce equity, diversity and inclusion has been made, but there is still more to do. Australia’s medical research workforce is made up of more than 18,000 staff and students, and while our workforce is predominantly made up of women, the majority of leadership positions are still held by men.